These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 16317826)

  • 1. Abatacept as add-on therapy for rheumatoid arthritis.
    Allison C
    Issues Emerg Health Technol; 2005 Sep; (73):1-4. PubMed ID: 16317826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of abatacept in the management of rheumatoid arthritis.
    Nogid A; Pham DQ
    Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.
    Reynolds J; Shojania K; Marra CA
    Pharmacotherapy; 2007 Dec; 27(12):1693-701. PubMed ID: 18041889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.
    Weinblatt M; Combe B; Covucci A; Aranda R; Becker JC; Keystone E
    Arthritis Rheum; 2006 Sep; 54(9):2807-16. PubMed ID: 16947384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis.
    Barr C
    J Infus Nurs; 2007; 30(2):96-104; quiz 120. PubMed ID: 17413494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
    N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
    Sherrer Y
    Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abatacept in the treatment of rheumatoid arthritis.
    Todd DJ; Costenbader KH; Weinblatt ME
    Int J Clin Pract; 2007 Mar; 61(3):494-500. PubMed ID: 17313619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
    Massarotti EM
    Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: a 1-week, randomized, double-blind, placebo-controlled trial.
    Lee EY; Lee EB; Park BJ; Lee CK; Yoo B; Lim MK; Shim SC; Sheen DH; Seo YI; Kim HA; Baek HJ; Song YW
    Clin Ther; 2006 Dec; 28(12):2052-60. PubMed ID: 17296461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis.
    Sibilia J; Westhovens R
    Clin Exp Rheumatol; 2007; 25(5 Suppl 46):S46-56. PubMed ID: 17977488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program.
    Weinblatt ME; Moreland LW; Westhovens R; Cohen RB; Kelly SM; Khan N; Pappu R; Delaet I; Luo A; Gujrathi S; Hochberg MC
    J Rheumatol; 2013 Jun; 40(6):787-97. PubMed ID: 23588946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
    Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures.
    Pincus T; Bergman MJ; Yazici Y; Hines P; Raghupathi K; Maclean R
    Rheumatology (Oxford); 2008 Mar; 47(3):345-9. PubMed ID: 18238788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab for rheumatoid arthritis.
    Palylyk-Colwell E; McGahan L
    Issues Emerg Health Technol; 2006 Sep; (89):1-4. PubMed ID: 17014062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.
    Tsao NW; Shojania K; Marra CA
    Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):9-18. PubMed ID: 24325566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B.
    Kim PS; Ho GY; Prete PE; Furst DE
    Arthritis Care Res (Hoboken); 2012 Aug; 64(8):1265-8. PubMed ID: 22392695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abatacept: new drug. Rheumatoid arthritis: after failure of TNF alpha antagonists and rituximab.
    Prescrire Int; 2008 Dec; 17(98):232. PubMed ID: 19422143
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.